Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women


About this study

The primary objective of this proposal is to conduct a study that assesses the safety, feasibility and efficacy of using PRP to treat this type of hair loss.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Only female patients are eligible
  2. Patients must be 18 years of age or older
  3. Patients must have Androgenic Alopecia Grade I-II by Ludwig Classification
  4. Patients must have been on stable birth control if premenopausal.
  5. Patients are able and willing to provide written informed consent after the nature of the study is fully explained

Exclusion Criteria:

  1. Patients with clinically abnormal hematology, serum chemistry, or screening laboratory results as reviewed by the Principal Investigator
  2. Patients who have undergone topical and systemic therapies for hair loss 3 months prior to the procedure
  3. Patients who have used any cosmetic product meant to address hair loss 3 months prior to enrollment
  4. Patients taking anti-rheumatic disease medication (including methotrexate or other anti-metabolites) within the 3 months prior to study entry.
  5. Patients previously having undergone hair transplant surgery prior to study entry
  6. Patients who are pregnant or currently breast-feeding children as Rogaine for Women is contra indicated for these women
  7. Patients who have taken spironolactone in the 3 months prior to study participation
  8. Patients with systemic, rheumatic or inflammatory disease or who are immunosuppressed
  9. Patients with ongoing infectious disease, including HIV and hepatitis
  10. Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer, or diabetes
  11. Patients participating in a study of an experimental drug or medical device within 30 days of study entry
  12. Patients with history of platelet disorders, bone marrow aplasia, sepsis, or cancer in the last 5 years.
  13. Patients taking antiaggregating therapy
  14. Patients on anticoagulant therapy
  15. Patients with tendency to keloid formation
  16. Patients with uncompensated diabetes
  17. Patients with active skin disease or skin infection at intended treatment areas

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Alison Bruce, M.B., Ch.B.

Closed for enrollment

More information


Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions